Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Adlego Biomedical AB
AB
Dissolved
Org 5566814116
Research and experimental development on biotechnology
·
NACE 7211
Est. 2005 · 21 years old
12 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on biotechnology
/
Adlego Biomedical AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
35M
26M
17M
9M
0M
2019: 18M
18M
2019
2020: 10M (-44% vs 2019)
10M
-44%
2020
2021: 17M (+70% vs 2020)
17M
+70%
2021
2022: 13M (-24% vs 2021)
13M
-24%
2022
2023: 28M (+115% vs 2022)
28M
+115%
2023
EBITDA
SEK millions
13M
8M
3M
-1M
-6M
2019: 3M
3M
2019
2020: -2M (-167% vs 2019)
-2M
-167%
2020
2021: 2M (+200% vs 2020)
2M
+200%
2021
2022: 1M (-50% vs 2021)
1M
-50%
2022
2023: 9M (+800% vs 2022)
9M
+800%
2023
Income statement
SEK thousands
Item
2023
2022
2021
2020
2019
Revenue
28 305
13 446
17 311
10 260
18 487
Staff expenses
—
−7 662
—
—
—
EBITDA
9 291
766
2 176
−1 920
2 508
Depreciation & amort.
−147
−93
−151
−103
−83
EBIT
9 144
673
2 025
−2 023
2 425
Net financials
−288
28
−45
−36
−12
Profit before tax
8 856
701
2 031
−80
1 757
Tax
−1 832
−388
−366
−0
−446
Net profit
7 024
314
1 665
−80
1 311
Balance sheet
SEK thousands
Item
2023
2022
2021
2020
2019
Total assets
14 073
18 364
22 286
14 499
9 933
Equity
9 712
2 688
5 374
3 709
3 789
Long-term debt
0
—
0
0
0
Short-term debt
4 362
15 676
16 912
10 739
4 114
Total debt
4 362
15 676
16 912
10 739
4 114
Financial ratios
5-year trend
EBITDA margin
32,8 %
This company
15,8 %
Market median
This company
Market median
108% above market
2019
2023
Equity ratio
69,0 %
This company
38,2 %
Market median
This company
Market median
81% above market
2019
2023
Return on equity
72,3 %
This company
18,4 %
Market median
This company
Market median
293% above market
2019
2023
Net profit margin
24,8 %
This company
8,1 %
Market median
This company
Market median
206% above market
2019
2023
Asset turnover
2,01×
This company
1,12×
Market median
This company
Market median
79% above market
2019
2023
Debt / equity
0,45×
This company
0,62×
Market median
This company
Market median
27% below market
2019
2023
Annual reports & filings
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
View
PDF
More on Adlego Biomedical AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
